USE OF JAK INHIBITORS FOR THE TREATMENT OF PAINFUL CONDITIONS INVOLVING NAV1.7 CHANNELS
An increasing body of evidence suggests that Nav1.7 encoded by SCN9A gene may play a key role in various pain states, including acute, inflammatory and/or neuropathic pain. The inventors now report an efficient treatment for severe cases of primary erythromelagia linked to a specific SCN9A mutation. In particular the inventors demonstrated that the inhibition of JAK2 produces a rightward shift in the voltage dependent activation of mutant Nav1.7 channels, thereby normalizing the function of mutant Nav1.7 channels. On this basis, the inventors treated a patient suffering from PE with very severe refractory pain with a JAK2 inhibitor (ruxolitinib) and showed the therapy leads to considerable reduction of pain. Accordingly, the present invention relates to the use of JAK inhibitors for the treatment of painful conditions involving Nav1.7 channels.
1 . A method of treating a painful condition involving Nav1.7 channels in a patient in need thereof comprising administering a therapeutically effective amount of a JAK inhibitor.
2 . The method of claim 1 wherein the painful condition is a nociceptive pain, a neuropathic pain, an inflammatory pain, a pathological pain, an acute pain, a subacute pain, a chronic pain, mechanical pain, chemical pain, a somatic pain, a visceral pain, deep somatic pain, superficial somatic pain, somatoform pain, allodynia, hyperalgesia, or a pain associated with a nerve injury.
3 . The method of claim 2 wherein the nociceptive pain includes visceral pain, deep somatic pain and superficial somatic pain.
4 . The method of claim 1 wherein the painful condition is caused by a gain of function mutation in SCN9A.
5 . The method of claim 7 the mutation is selected from the group consisting of Q10R, F216S, S241T, N395K, E406K, I859T, L869F, L869H, F1460V, A1643E and A1643T in SEQ ID NO: 1.
6 . The method of claim 4 wherein the painful condition is primary erythermalgia.
7 . The method of claim 1 wherein the JAK inhibitor is ruxolitinib.
8 . The method of claim 1 wherein JAK inhibitor is a selective JAK2 inhibitor.
9 . The method of claim 8 wherein the selective JAK2 inhibitor is selected from the group consisting of Fedratinib, Gandotinib, Lestaurtinib, and Pacritinib.
10 . The method of claim 1 wherein the JAK inhibitor is administered to the patient in a form of a topical formulation.